For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251127:nRSa1613Ja&default-theme=true
RNS Number : 1613J Cirata PLC 27 November 2025
27 November 2025
Cirata plc
("Cirata" or the "Company")
Financial Conduct Authority Update
Cirata plc (LSE: CRTA) has been notified by the Financial Conduct Authority
that its investigation into the Company has been closed and no action will be
taken against the Company. The investigation was first announced to the market
on 20 April 2023 and concerned the period 1 May 2021 to 9 March 2023 and
whether certain regulatory announcements released by the Company may have
materially mis-stated the Company's financial position.
Stephen Kelly CEO Commented:
The new management team tasked with rescuing the company from the brink after
the dark days of March 2023, have worked tirelessly to build a company that
the UK tech sector can be proud of. As we close out the year, we continue to
make progress- with a new cost structure, the release of Cirata Symphony -a
new Data Orchestration Platform- and a laser focus on growth. The announcement
today heralds one sad chapter closed and a new chapter beginning.
This announcement contains inside information under the UK Market Abuse
Regulation. The person responsible for arranging the release of this
announcement on behalf of Cirata plc is Stephen Kelly, Chief Executive
Officer.
For further information, please contact:
Cirata Via FTI Consulting
Stephen Kelly, Chief Executive Officer
Ricardo Moura, Chief Financial Officer
Dan Hayes, Investor Relations
FTI Consulting +44 (0) 20 3727 1137
Matt Dixon / Kwaku Aning / Usama Ali
Stifel (Nomad and Joint Broker) +44 (0) 20 7710 7600
Fred Walsh / Brough Ransom / Ben Good
Panmure Liberum (Joint Broker) +44 (0) 20 3100 2000
Rupert Dearden / John More
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END MSCFLFIDLVLRFIE
Copyright 2019 Regulatory News Service, all rights reserved